During the tough times of the novel Coronavirus posing a serious threat, the Drug Controller General of India (DCGI) gave its nod for the emergency use of vaccines, Covishield and Bharat Biotech's Covaxin. The vaccines were approved with some restrictions.
TRS working President and IT Minister Kalvakuntla Taraka Rama Rao aka KTR heaped praises on the Hyderabad-based Bharat Biotech after the vaccine developed by the firm got DCGIâs approval.
He took to the microblogging site Twitter to congratulate the multidimensional biotechnology company. He has also congratulated Bharat Biotech Chairman and Managing Director Dr. Krishna Ella, and the time of Scientists involved in this.
"Many Congratulations to Dr. Krishna Ella, Suchitra Ella & the entire team of scientists of BharatBiotech on getting DCGI approval for Covaxin. Hyderabad continues to shines on as the vaccine capital because of the pursuit of excellence of scientists & innovative entrepreneurs," KTR's tweet reads.
Hyderabad-based Bharat Biotech joined hands with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV) to indigenously develop the Covaxin vaccine.
The second vaccine approved by the DCGI is Covishield developed by the Pune-based Serum Institute of India. The SII collaborated with Oxford University and pharma major AstraZeneca
The vaccine doses developed by both firms are expected to be rolled out very soon. The official statement on the vaccine rollout is expected to come in a couple of weeks.
TRS working President and IT Minister Kalvakuntla Taraka Rama Rao aka KTR heaped praises on the Hyderabad-based Bharat Biotech after the vaccine developed by the firm got DCGIâs approval.
He took to the microblogging site Twitter to congratulate the multidimensional biotechnology company. He has also congratulated Bharat Biotech Chairman and Managing Director Dr. Krishna Ella, and the time of Scientists involved in this.
"Many Congratulations to Dr. Krishna Ella, Suchitra Ella & the entire team of scientists of BharatBiotech on getting DCGI approval for Covaxin. Hyderabad continues to shines on as the vaccine capital because of the pursuit of excellence of scientists & innovative entrepreneurs," KTR's tweet reads.
Hyderabad-based Bharat Biotech joined hands with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV) to indigenously develop the Covaxin vaccine.
The second vaccine approved by the DCGI is Covishield developed by the Pune-based Serum Institute of India. The SII collaborated with Oxford University and pharma major AstraZeneca
The vaccine doses developed by both firms are expected to be rolled out very soon. The official statement on the vaccine rollout is expected to come in a couple of weeks.